Jamie Stokke1,2, Lillian Sung3, Abha Gupta3,4, Antoinette Lindberg1,2, Abby R Rosenberg1,2,5,6. 1. Seattle Children's Hospital, Seattle, Washington. 2. University of Washington, Seattle, Washington. 3. Hospital for Sick Children, Toronto, Ontario, Canada. 4. University of Toronto, Toronto, Ontario, Canada. 5. Fred Hutchinson Cancer Research Center, Seattle, Washington. 6. Treuman Katz Center for Pediatric Bioethics, Seattle, Washington.
Abstract
BACKGROUND: Pediatric, adolescent, and young adult survivors of bone sarcomas are at risk for poor quality of life (QOL). We conducted a systematic review and meta-analysis to summarize the literature describing QOL in this population and differences in QOL based on local control procedures. PROCEDURE: Included studies described ≥5 patients <25 years old who had completed local control treatment for bone sarcoma, defined QOL as a main outcome, and measured it with a validated instrument. Data extraction and quality assessments were conducted with standardized tools. Meta-analyses compared QOL based on surgical procedure (limb-sparing vs. amputation) and were stratified by assessment type (objective physical function, clinician-assessed disability, patient-reported disability, and patient-reported QOL). Effect sizes were reported as the standard mean difference when multiple instruments were used within a comparison and weighted mean difference otherwise. All were weighted by inverse variance and modeled with random effects. RESULTS: Twenty-two of 452 unique manuscripts were included in qualitative syntheses, eight of which were included in meta-analyses. Manuscripts were heterogeneous with respect to included patient populations (age, tumor type, time since treatment) and QOL instruments. Prospective studies suggested that QOL improves over time, and that female sex and older age at diagnosis are associated with poor QOL. Meta-analyses showed no differences in outcomes between patients who underwent limb-sparing versus amputation for local control. CONCLUSION: QOL studies among children and AYAs with bone sarcoma are remarkably diverse, making it difficult to detect trends in patient outcomes. Future research should focus on standardized QOL instruments and interpretations.
BACKGROUND: Pediatric, adolescent, and young adult survivors of bone sarcomas are at risk for poor quality of life (QOL). We conducted a systematic review and meta-analysis to summarize the literature describing QOL in this population and differences in QOL based on local control procedures. PROCEDURE: Included studies described ≥5 patients <25 years old who had completed local control treatment for bone sarcoma, defined QOL as a main outcome, and measured it with a validated instrument. Data extraction and quality assessments were conducted with standardized tools. Meta-analyses compared QOL based on surgical procedure (limb-sparing vs. amputation) and were stratified by assessment type (objective physical function, clinician-assessed disability, patient-reported disability, and patient-reported QOL). Effect sizes were reported as the standard mean difference when multiple instruments were used within a comparison and weighted mean difference otherwise. All were weighted by inverse variance and modeled with random effects. RESULTS: Twenty-two of 452 unique manuscripts were included in qualitative syntheses, eight of which were included in meta-analyses. Manuscripts were heterogeneous with respect to included patient populations (age, tumor type, time since treatment) and QOL instruments. Prospective studies suggested that QOL improves over time, and that female sex and older age at diagnosis are associated with poor QOL. Meta-analyses showed no differences in outcomes between patients who underwent limb-sparing versus amputation for local control. CONCLUSION: QOL studies among children and AYAs with bone sarcoma are remarkably diverse, making it difficult to detect trends in patient outcomes. Future research should focus on standardized QOL instruments and interpretations.
Authors: Victoria G Marchese; Susan Ogle; Richard B Womer; John Dormans; Jill P Ginsberg Journal: Pediatr Blood Cancer Date: 2004-01 Impact factor: 3.167
Authors: Anthony N Audino; Nicholas D Yeager; Lindsey Asti; Yongjie Miao; Sarah H O'Brien Journal: Pediatr Blood Cancer Date: 2012-06-15 Impact factor: 3.167
Authors: Jill P Ginsberg; Shesh N Rai; Claire A Carlson; Anna T Meadows; Pamela S Hinds; Elena M Spearing; Lijun Zhang; Lulie Callaway; Michael D Neel; Bhaskar N Rao; Victoria G Marchese Journal: Pediatr Blood Cancer Date: 2007-12 Impact factor: 3.167
Authors: Victoria G Marchese; Elena Spearing; Lulie Callaway; Shesh N Rai; Lijun Zhang; Pamela S Hinds; Claire A Carlson; Michael D Neel; Bhaskar N Rao; Jill Ginsberg Journal: Pediatr Phys Ther Date: 2006 Impact factor: 3.049
Authors: Lillian Sung; Theo Zaoutis; Nicole J Ullrich; Donna Johnston; Lee Dupuis; Elena Ladas Journal: Pediatr Blood Cancer Date: 2012-12-19 Impact factor: 3.167
Authors: Michael W Bishop; Kirsten K Ness; Chenghong Li; Wei Liu; Deo Kumar Srivastava; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Alberto S Pappo; Leslie L Robison; Melissa M Hudson; Daniel A Mulrooney Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-06-04 Impact factor: 4.254
Authors: Hans Lapica; Matan Ozery; Harsha Raju; Grettel Castro; Pura Rodriguez de la Vega; Noël C Barengo Journal: Int J Environ Res Public Health Date: 2022-05-22 Impact factor: 4.614
Authors: J Vetsch; C E Wakefield; E G Robertson; T N Trahair; M K Mateos; M Grootenhuis; G M Marshall; R J Cohn; J E Fardell Journal: Qual Life Res Date: 2018-01-25 Impact factor: 4.147
Authors: Elizabeth Donovan; Sarah R Martin; Laura C Seidman; Lonnie K Zeltzer; Tara M Cousineau; Laura A Payne; Marla Knoll; Margorie Weiman; Noah C Federman Journal: J Adolesc Young Adult Oncol Date: 2021-04-12 Impact factor: 2.223
Authors: Andrés Redondo; Silvia Bagué; Daniel Bernabeu; Eduardo Ortiz-Cruz; Claudia Valverde; Rosa Alvarez; Javier Martinez-Trufero; Jose A Lopez-Martin; Raquel Correa; Josefina Cruz; Antonio Lopez-Pousa; Aurelio Santos; Xavier García Del Muro; Javier Martin-Broto Journal: Cancer Chemother Pharmacol Date: 2017-10-16 Impact factor: 3.333
Authors: Kirsten K Ness; Melissa M Hudson; Kendra E Jones; Wendy Leisenring; Yutaka Yasui; Yan Chen; Marilyn Stovall; Todd M Gibson; Daniel M Green; Joseph P Neglia; Tara O Henderson; Jacqueline Casillas; Jennifer S Ford; Karen E Effinger; Kevin R Krull; Gregory T Armstrong; Leslie L Robison; Kevin C Oeffinger; Paul C Nathan Journal: Ann Intern Med Date: 2016-11-08 Impact factor: 25.391